Safety and efficacy of recombinant human endostatin (Endostar (R)) in combination with platinum-based doublet chemotherapy for the treatment of advanced non-small cell lung cancer: a national wide, open,multi-center, and phase Ⅳ clinical study

Endostar Phase Ⅳ Study Group

doi:10.3969/j.issn.1009-0460.2019.04.001

Home>Articles>Safety and efficacy of recombinant human endostatin (Endostar (R)) in combination with platinum-based doublet chemotherapy for the treatment of advanced non-small cell lung cancer: a national wide, open,multi-center, and phase Ⅳ clinical study

DOI: 10.3969/j.issn.1009-0460.2019.04.001

Safety and efficacy of recombinant human endostatin (Endostar (R)) in combination with platinum-based doublet chemotherapy for the treatment of advanced non-small cell lung cancer: a national wide, open,multi-center, and phase Ⅳ clinical study

Endostar Phase Ⅳ Study Group

Machine-generated Keywords：

Publication Date：2019-01-01

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：10( 289-298 )

Chinese Clinical Oncology

PKUISTIC

ISSN：1009-0460

Year, Vol.(Issue)：2019,24(4)